Overview

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

Status:
Recruiting
Trial end date:
2024-12-20
Target enrollment:
Participant gender:
Summary
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with Neuroendocrine Tumor
Phase:
Phase 1
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
Octreotide